StockUS listing USCSPHFPINKHealthcareEarnings Deterioration

CStone Pharmaceuticals(CSPHF) Stock Analysis | Healthcare

USD --+0.00%
Reward50Moderate
Risk39Moderate
75%Data
Thin -186% profit margin · Revenue down 81% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.22Bn
Reward Ratingⓘ50 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ39 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CSPHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is CStone Pharmaceuticals?

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally.

AI Brief Pro

The brief on CStone Pharmaceuticals

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is CStone Pharmaceuticals?

CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.22B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.521
Insider Activity
12M windowNo data
No insider activity data available for this ticker.